In this study, we investigated whether differences in immunoglobulin product concentrations affect the efficacy and safety of acute phase treatment for KD. The use of 10% immunoglobulin products significantly reduced the IVIG infusion duration…
Impact of 10% vs. 5% immunoglobulin products on treatment outcomes in Kawasaki disease: a multicenter retrospective study
